Positive data have been reported from a phase 3 study of once-weekly prophylaxis with subcutaneous emicizumab (Chugai/Roche/Genentech) in adults and adolescents with hemophilia A who have inhibitors to factor VIII.

The FDA has approved betrixaban (Bevyxxa, Portola Pharmaceuticals), the first anticoagulant for hospital and extended-duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors

Despite dramatic reductions in the death rate from cardiovascular disease, it remains the leading cause of death, and experts have expressed concern that the number of new therapies coming to market has lagged.

A little more than half of all opioid prescriptions in the United States are written for patients with anxiety, depression, and other mood disorders, according to a new study described on the STAT website.

Republican Senator Susan Collins of Maine has announced that she has “extreme reservations” about the Senate’s health care bill and does not think it will pass this week, according to a Reuters report.

Exondys 51 is being touted as a miracle drug for those suffering from the rare disease Duchenne muscular dystrophy. But, as the New York Times reports, insurers are balking at the exorbitant price for a medication whose long-term clinical benefits have yet to be measured.

The FDA has granted breakthrough therapy status to CR845 (Cara Therapeutics), a peripherally acting kappa opioid receptor agonist, for the treatment of moderate-to-severe uremic pruritus (UP) in patients with chronic kidney disease (CKD) undergoing hemodialysis.

The FDA has given the go-ahead to Rituxan Hycela (rituximab and hyaluronidase human, Genentech) for subcutaneous (SC) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma; previously untreated diffuse large B-cell lymphoma (DLBCL); and previously untreated and previousl

Around the world, scientists are conducting clinical trials to transform stem cells––which make endless copies of themselves––into other types of cells, such as lung, brain, heart, or muscle cells, and use the new cells to cure ailments ranging from diabetes to heart disease, according to a presentation by Professor Janet Rossant at the Royal Society Comm

For the hundreds of rural U.S. hospitals struggling to stay in business, health policy decisions made in Washington, D.C., this summer could make survival a lot harder, according to a report from Kaiser Health News.

President Donald Trump has acknowledged that a lack of support from four Senate Republicans leaves the party’s health care overhaul on a “very, very narrow path” to win passage, but signaled a willingness to work with them to make changes, according to a Reuters report.

GlaxoSmithKline (GSK) has presented new results from a late-stage clinical study showing that its candidate vaccine for the prevention of herpes zoster (shingles) in people 50 years of age or older, Shingrix, induces a strong immune response in older adults who have been vaccinated against shingles with the currently available live-attenuated zoster (ZVL)

A review published in Clinical Chemistry has identified 10 genes that show promise in predicting how patients will respond to opioid pain medications. Using these genetic markers, health care providers could potentially tailor opioid therapy better to curb the skyrocketing rate of deaths from these drugs, the authors claim.

When Senate Republicans unveil their plan to overhaul the Patient Protection and Affordable Care Act (PPACA), they will face a skeptical public that already doesn’t buy the justification for an earlier version that passed the House of Representatives, according to a new Reuters/Ipsos survey.

Approximately half a million clinicians who participated in the Centers for Medicare and Medicaid Services’ (CMS) Physician Quality Reporting System (PQRS) will be hit with a 2% Medicare penalty this year because they didn’t meet program requirements, according to a report from FierceHealthcare.